Sequana Medical N : announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure -November 29, 2023 at 11:43 am EST

PRESS RELEASE


REGULATED INFORMATION - INSIDE INFORMATION


29 November 2023, 07:00 am CET



Data from all three patients in non-randomized...

Related Keywords

United States ,Belgium ,Canada ,American , ,York Heart Association ,Company Or Sequanamedical ,Euronext Brussels ,Chief Medical Officer ,Sequana Medical ,Safety Monitoring Board ,New York Heart Association ,Seattle Heart Failure ,North American ,Pre Market Approval ,Data Safety Monitoring Board ,Glomerular Filtration Rate ,Markets ,